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ABSTRACT
Here we explore the role of the interplay between host immune response and 
epithelial-mesenchymal-transition (EMT)-Type tumor-budding on the outcome of 
pancreatic adenocarcinoma (PDAC).
CD4+, CD8+, and FOXP3+T-cells as well as iNOS+ (M1) and CD163+-
macrophages (M2) were assessed on multipunch tissue-microarrays containing 120 
well-characterized PDACs, precursor lesions (PanINs) and corresponding normal 
tissue. Counts were normalized for the percentage of tumor/spot and associated 
with the clinico-pathological features, including peritumoral (PTB) and intratumoral 
(ITB) EMT-Type tumor-budding and outcome.
Increased FOXP3+T-cell-counts and CD163-macrophages and decreased 
CD8+T-cell-counts were observed in PDACs compared with normal tissues and 
PanINs (p < 0.0001). Increased peritumoral FOXP3+T-cell-counts correlated 
significantly with venous invasion, distant metastasis, R1-status, high-grade ITB, 
PTB and independently with reduced survival. Increased intratumoral FOXP3+T-
cells correlated with lymphatic invasion, N1-stage, PTB and marginally with adverse 
outcome. High peritumoral CD163-counts correlated with venous invasion, PTB and 
ITB. High intratumoral CD163-counts correlated with higher T-stage and PTB.
PDAC-microenvironment displays a tumor-favoring immune-cell composition 
especially in the immediate environment of the tumor-buds that promotes further 
growth and indicates a close interaction of the immune response with the EMT-
process. Increased peritumoral FOXP3+T-cell density is identified as an independent 
adverse prognostic factor in PDAC. Patients with phenotypically aggressive PDACs 
may profit from targeted immunotherapy against FOXP3.
INTRODUCTION
PDAC is a highly lethal malignancy refractory 
to standard therapies and characterized by a striking 
desmoplastic reaction of the stromal compartment 
[1, 2]. A recent report from the Pancreatic Cancer 
Action Network estimates that by 2020, PDAC will 
become the second leading cause of cancer-related 
death [3, 4]. Despite recent advances with combination 
chemotherapy to date PDAC remains a significant 
medical problem that requires an innovative and novel 
therapeutic approach [5].
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The tumor microenvironment plays an important 
role in the biological behavior of cancer [6] and the host 
immune reaction, as represented by the peritumoral and 
intratumoral immune cell infiltrates, is one of its main 
players [7–12]. Although supposed to be a manifestation of 
the immune response against neoplastic cells [13, 14], the 
presence of immune cell infiltrates in the microenvironment 
of various cancers does not always have a positive 
influence on patient outcome. Especially FOXP3+T-cells 
and M2-polarized macrophages have been shown to have 
an anti-inflammatory function and to suppress anti-tumor 
immunity thus promoting tumor cell survival [15, 16].
In many gastrointestinal carcinomas, including 
pancreatic cancer, epithelial-mesenchymal transition (EMT), 
histomorphologically represented by the presence of tumor 
budding, is a hallmark of aggressive behavior [17–20]. 
Moreover, it is thought that tumor buds may possess stem-
cell like features and represent migrating cancer cells 
[21]. Tumor budding was inversely correlated to CD8+ 
T-cell counts at the advancing edge of colorectal cancer, 
suggesting that T-cell infiltrates may represent a defense 
mechanism against tumor budding cells [22]. However, 
little is known on the interaction between tumor buds and 
the immune response in the microenvironment of PDAC.
To address this issue, we performed an analysis of 
the immune cell infiltrates in the microenvironment of 
surgically resected PDACs in correlation with EMT-Type 
tumor budding and other clinicopathological features, by 
using multiple punch tissue microarrays. In addition, we 
compare the immune cell counts in the microenvironment 
of PDAC with that of precursor lesions (pancreatic 
intraepithelial neoplasia: PanIN) and of non-neoplastic 
pancreatic tissue. We hypothesize that an EMT-Type 
high-grade tumor budding phenotype is associated with 
privileged immune conditions, conferring to budding 
cells a survival benefit by evading the host defense. The 
combined assessment of the host immune response with 
factors of tumor aggressiveness like tumor budding could 
help us to achieve superior prognostic stratification of the 
patients than either factor alone.
RESULTS
Patient characteristics
Tissues from 120 patients with PDAC were included 
in the tissue microarray. Study design is outlined in Suppl. 
Figure 1. Median overall survival (OS) for the cohort of 
120 patients was 12.9 months (95%CI: 10–13), while the 
median disease-free interval (DFI) was 5.9 months (95%CI: 
4–6). Patient characteristics are outlined in Suppl. Table 1.
Normal-PanIN-Carcinoma sequence
A significant progressive increase in overall 
FOXP3+T-cell-counts and CD163-macrophages (M2) 
was found between normal pancreatic tissue, PanINs and 
PDACs (p = 0.0114, Figure 1, Table 1). The opposite 
was true for the CD8+T-cell infiltrates which were found 
to be markedly decreased in PDACs compared with 
normal tissues and PanINs (p < 0.0001, Table 1). These 
differences were more noticeable when taking into account 
the peritumoral/perilesional cell counts (p). Intraepithelial 
immune cell counts (i) were in general very low (Table 1). 
In PDACs a strong negative correlation between 
peritumoral CD8+T-cell counts and tumor budding was 
observed (p = 0.01, Figure 2).
Association with clinicopathological features
Results for all markers for associations with 
clinicopathological features when considering all 
patients and using the median normalized cell counts are 
summarized in Suppl. Table 2. Representative examples 
of the immune cell infiltrates in the microenvironment 
of PDAC are depicted in the Figures 2 and 3. Increased 
peritumoral FOXP3+T-cell-counts (FOXP3p) correlated 
with high-grade tumor budding including budding 
10-in-10 (p = 0.0425) previously assessed in whole 
tissue sections, as well as ITB (p = 0.0428) and PTB 
(p < 0.0001), assessed at the TMA spots for each protein 
and showed significant correlation with the presence 
of venous invasion (p = 0.0189), distant metastasis (p 
= 0.0073) and positive resection margins (p = 0.0067) 
(Table 2). Increased intratumoral FOXP3+T-cells 
correlated with lymphatic invasion (p = 0.0062), 
N-stage (p = 0.0022) and PTB (p = 0.0041, Table 2). 
High peritumoral CD163-counts (CD163p) correlated 
with venous invasion (p = 0.0291), budding 10-in-10 
(p = 0.0155), PTB (p = 0.0200) and ITB (p = 0.0253, 
Table 3). High intratumoral CD163-counts (CD163i) 
correlated significantly with T-stage (p = 0.006) and PTB 
(p = 0.0349, Table 3).
Prognostic significance
Regarding prognosis, reduced peritumoral CD8+T-
cell counts were associated with worse survival time of 
the patients in the univariate (p = 0.0372) but not in the 
multivariate analysis when adjusted for T-, N-, M-stage, 
tumor budding and therapy (p = 0.8862, Suppl. Table 3).
On the contrary, increased peritumoral FOXP3+T-
cell counts showed a significant association with worse 
outcome and were found to be an independent prognostic 
factor in the multivariate analysis, when adjusted for T-, 
N-, M-stage, tumor budding and therapy (p = 0.0027, 
Table 4, Figure 4) and when adjusted for the other 
immune cell counts (Suppl. Table 4). Intratumoral 
FOXP3+T-cell counts showed a marginal association 
with reduced survival (p = 0.0572, Table 2). No 
association with patient outcome was found for CD4, 
CD163 and iNOS counts.
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DISCUSSION
Here we show that the tumor microenvironment of 
phenotypically aggressive PDAC is characterized by the 
presence of EMT-Type tumor budding cells surrounded 
by numerous pro-tumoral leukocytes such as FOXP3+T-
cells and CD163+ (M2-polarized) macrophages with 
concomitant reduction of anti-tumoral immune cell 
populations such as CD8+T-cells and iNOS+ (M1-
polarized) macrophages, thus creating a privileged 
immune environment for the further tumor growth and 
metastasis.
According to Hanahan & Weinberg [6] neoplastic 
cells are often capable of driving inflammatory pathways 
that recruit pro-tumoral leukocytes to the tumor 
microenvironment and can actively evade attack and 
elimination by the immune host response. This escape 
of the host immune defense by the neoplastic cells is 
considered to be an essential step towards metastatic 
spread. Our data suggests that budding cells may indeed 
interact with their immunological microenvironment 
during EMT-process. Thus, tumor budding was found 
to be particularly prominent when reduced numbers of 
peritumoral CD8+T-cells were present. On the contrary, 
when the host was able to maintain a strong anti-tumoral 
immune response including numerous CD8+T-cells, 
tumor budding was almost absent. One hypothesis may 
be that host response is capable of destroying budding 
cells at the invasive front. Alternatively, this could signal 
the existence of a budding cell population with more 
Figure 1: Examples of FOXP3 staining. (A) Normal pancreatic tissue with low counts of FOXP3+ T-cells, x100 (Bar:100μm); 
(B) PanIN with moderate FOXP3+-T-cell infiltrates, x100 (Bar:100μm); (C) PDAC with numerous peritumoral FOXP3+T-cells x100 
(Bar:100μm); (D) PDAC with numerous peritumoral FOXP3+T-cells, x400 (Bar:50μm).
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antigenic phenotype that has yet to acquire the ability 
to evade immunosurveillance. Furthermore, our results 
are partly in line with previous studies that showed that 
tumor infiltration by higher numbers both of CD4+T-cells 
and CD8+T-cells was associated with longer survival 
of PDAC patients [23]. However, in the present study, 
increased counts of peritumoral CD8+T-cells were 
associated with better prognosis in univariate but not in 
the multivariate analysis, indicating that increased CD8+ 
infiltrates alone are not sufficient for a better outcome. 
CD4+T-cell counts did not have an impact on survival 
in our study.
A high density of tumor-infiltrating FOXP3 Tregs 
has been associated with poor outcome in various solid 
tumors, including ovarian [24, 25], pancreatic [26] 
and hepatocellular carcinoma [27, 28]. In the present 
study, high-grade tumor budding was associated with 
increased counts of peritumoral FOXP3+T-cells. 
Moreover, FOXP3+T-cells added independent prognostic 
information for PDAC patients in a multivariate model 
including other established and independent prognostic 
factors such as tumor budding. This could be explained by 
the proposed role of these cells in suppressing anti-tumor 
immunity and in helping tumor cells escape detection by 
the host’s immune defense system [29]. Moreover, in line 
with previous reports [26], the prevalence of FOXP3+T-
cells increased significantly during the neoplastic 
progression. Taken together and in consistence with 
previous data, we identify a significant survival advantage 
and favourable histopathological features, such as absence 
of an EMT-type tumor budding, in PDAC patients with 
CD8+/FOXP3- phenotype, suggesting a close interaction 
of the immune cells with the molecular pathways that 
control the EMT process.
Although the role of the innate immune cells of the 
myeloid lineage such as tumor-associated macrophages 
(TAMs) in the tumor development has been recognized, 
only few previous reports indicate a role of macrophages 
in EMT [30–32]. Our results, by demonstrating a strong 
association between CD163 + (M2) macrophages and 
tumor budding, support an EMT-promoting role for M2-
macrophages. Activated macrophages can be divided 
into M1 and M2 phenotype [33] even if it is clear that 
these are two extremes of a spectrum of differentiation. 
While M1 macrophages mediate resistance against tumors 
and elicit tissue disruptive reactions, M2 macrophages 
have an immune suppressive role [34, 35]. Especially 
in pancreatic cancer high numbers of M2 macrophages 
were associated with larger tumor size, local recurrence 
and shortened survival [36]. Kurahara and colleagues 
[33] described an elevated incidence of M2 macrophages 
in PDAC tissues, correlating with increased nodal 
lymphangiogenesis and poor prognosis partially due to 
accelerated lymphatic metastasis, but the mechanism by 
which these cells influence the progression of pancreatic 
cancer is not yet clear. Our findings suggest that a possible 
mechanism could be through the promotion of EMT-type 
tumor budding. Moreover, recent evidence suggests that 
the phenotype of TAMs varies with the stage of tumor 
progression. During cancer progression, macrophages 
switch from an M1- to an M2-like phenotype as the 
tumor begins to invade, vascularize and develop [37–39]. 
In agreement with this, we find a progressive decrease 
of iNOS+ (M1) and an increase of CD163+ (M2) 
macrophages from the normal tissue, to PanINs and to 
invasive cancer. Taken together our findings underline the 
role of TAMs in the pancreatic tumorigenesis and provide 
support for their association with the process of EMT.
Table 1: Differences in average cell counts of the different markers across histology
Normal PanIN PDAC P-value*
Average No. Average No. Average No.
CD8p 107.6 90.3 58.1 0.0114
CD8i 13 4.2 0.6 <0.0001
CD4p 14.2 57.8 22.5 <0.0001
CD4i 0.09 2.03 0.3 <0.0001
FOXP3p 3.6 7.1 10.9 <0.0001
FOXP3i 0 0.12 0.5 <0.0001
CD163 (M2)p 115.1 140 153.4 0.0016
CD163 (M2)i 1.1 3.16 3.6 <0.0001
iNOS (M1)p 4.32 1 0.38 <0.0001
iNOS (M1)i 0.17 0 0 0.006
PanIN: Pancreatic Intraepithelial Neoplasia; PDAC: Pancreatic Ductal Adenocarcinoma; p: pericellular/perilesional/ and/or 
peritumoral localisation; i: intracellular/ntralesional/ and/or intratumoral localisation
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Figure 2: CD8/Pancytokeratin double staining demonstrating a strong negative correlation between EMT-type tumor 
budding and CD8+T-cells. (A and B) Examples of PDAC with numerous peritumoral CD8+T-cells and absence of tumor buds, x100  
(Bar:100 μm); (C and D) PDACs with high-grade tumor budding and markedly reduced peritumoral CD8+T-cell counts, x100 (Bar:100 μm); 
(E) PDAC with numerous peritumoral CD8+T-cells and absence of tumor buds, x400 (Bar:50μm); (F) PDAC with high-grade tumor 
budding and markedly reduced peritumoral CD8+T-cell counts, x400 (Bar:50 μm).
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Our results should be understood in the context 
of the study limitations. Although TMAs provide 
an efficient and cost-effective tool for testing a 
comprehensive panel of potential biomarkers on a 
large number of tumor specimens, the TMA technique 
could raise concerns related to the sampling of 
large, heterogeneous tumors. The effect of tumor 
heterogeneity was minimized by sampling at least two 
punches from the center and two from the invasive 
front and evaluating the average protein expression 
across the total number of samples. Our study may 
further be limited by the fact that all cases come from 
a single center. Nonetheless, our study benefits from 
complete clinicopathological data with information on 
adjuvant therapy and follow-up and the adherence to the 
REMARK guidelines which are essential for proposing 
prognostic biomarkers [40].
In conclusion, our findings suggest that in the 
tumor microenvironment of PDAC, EMT-type budding 
cells are surrounded by a tumor-favoring composition 
of the immune cell infiltrates, promoting further tumor 
growth and metastatic spread and indicating a close 
interaction of the immune response with the EMT 
process. Increased peritumoral FOXP3+T-cell density 
could be identified as an independent adverse prognostic 
factor in PDAC. Patients with resected, phenotypically 
aggressive PDACs may thus profit from a postoperative 
targeted immunotherapy against FOXP3. The combined 
assessment of host-associated factors such as immune 
response and tumor-associated factors such as EMT-
type tumor budding could help us to achieve superior 
prognostication and patient stratification than either 
factor alone.
MATERIALS AND METHODS
Patients and specimen characteristics
This study complies with the REMARK guidelines 
for tumor marker prognostic studies [40]. The study design 
is outlined in Figure 1. Non-consecutive PDAC cases from 
120 patients, surgically treated between 2000 and 2010, 
were included. Paraffin-embedded tissue blocks of primary 
tumors were retrieved from the Department of Pathology, 
Aretaieion University Hospital, University of Athens 
Medical School, Greece. All histomorphological data were 
reviewed from the corresponding hematoxylin and eosin 
(H&E) stained slides, while clinical data were obtained 
from chart reports. Clinicopathological information for all 
patients included age, gender, tumor diameter, number of 
positive lymph nodes and total number of lymph nodes 
harvested, TNM stage (7th Edition), perineural, as well as 
blood vessel and lymphatic invasion and resection margin 
status (R-status). Information on post-operative therapy 
was available for all patients (Suppl. Table 1). The use of 
this material was approved by the local ethics committees 
of the University of Athens and University of Bern (Ref.-
Nr. KEK-BE: 200/2014).
Figure 3: Snapshots of the tumor microenvironment of PDAC demonstrating tumor budding cells surrounded by 
numerous FOXP3+T-cells (A, x400, Bar:50μm); moderate counts of CD4+T-cells (B, x400, Bar:50μm); isolated iNOS-
macrophages (C, x400, Bar:50μm) and dense infiltrates of CD163-macrophages (D, x400, Bar:50μm).
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Assay methods
Construction of tissue microarrays (TMA)
For each patient, the hematoxylin and eosin slides 
of the primary tumor from the corresponding whole tissue 
sections were evaluated and representative areas of the 
tissue were marked using a felt-tip pen for easy detection. 
Punches were taken from formalin-fixed, paraffin-
embedded blocks using a tissue cylinder with a diameter 
of 0.6 mm and were subsequently transferred into 1 
recipient paraffin block (3 × 2.5 cm) using a homemade 
Table 2: Association of FOXP3 positive cells, peritumoral (p) and intratumoral (i) and 
clinicopathological features in PDAC
Feature FOXP3p FOXP3i
Freq N (%) P-value Freq N (%) P-value
Low High Low High
Gender Female 21 (36.2) 27 (54.0) 0.0635 24 (43.6) 24 (45.3) 0.8633
Male 37 (63.8) 23 (46.0) 31 (56.4) 29 (54.7)
Grade G1-2 8 (13.6) 7 (14.0) 0.9469 7 (12.5) 8 (15.1) 0.6943
G3 51 (86.4) 43 (86.0) 49 (87.5) 45 (84.9)
pT pT1-2 5 (8.6) 6 (12.2) 0.5385 6 (11.1)  5 (9.4) 0.7752
pT3 53 (91.4) 43 (87.8) 48 (88.9) 48 (90.6)
pN pN0 8 (13.8) 10 (20.4) 0.4402 15 (27.8) 3 (5.7) 0.0022
pN1 50 (86.2) 39 (79.6) 39 (72.2) 50 (94.3)
pM pM0 50 (86.2) 49 (100.0) 0.0073 51 (94.4) 48 (90.6) 0.4886
pM1 8 (13.8) 0 (0.0) 3 (5.6) 5 (9.4)
L L0 11 (19.0) 8 (16.3) 0.7219 15 (27.8) 4 (7.6) 0.0062
L1 47 (81.0) 41 (83.7) 39 (72.2) 49 (92.5)
V V0 57 (95.0) 38 (77.6) 0.0189 46 (85.2) 39 (73.6) 0.1377
V1 3 (5.0) 11 (22.5) 8 (14.8) 14 (26.4)
R R0 34 (59.7) 41 (83.7) 0.0067 35 (66.0) 40 (75.5) 0.1954
R1 23 (40.3) 8 (16.3) 18 (34.0) 13 (24.5)
Chemotherapy None 1 (1.9) 2 (4.2) 0.6031 1 (1.9) 2 (4.2) 0.6031
Yes 52 (98.1) 46 (95.8) 52 (98.1) 46 (95.8)
Radiotherapy None 20 (74.1) 40 (87.0) 0.2098 22 (78.6) 38 (84.4) 0.5441
Yes 7 (25.9) 6 (13.0) 6 (21.4) 7 (15.6)
Budding 10-in-10 Low 20 (37.0) 10 (20.8) 0.0425 17 (34.7) 13 (24.5) 0.2843
High 34 (63.0) 38 (79.2) 32 (65.3) 40 (75.5)
ITB (per punch) Low 30 (52.6) 16 (32.0) 0.0428 26 (47.3) 17 (32.7) 0.1674
High 27 (47.4) 34 (68.0) 29 (52.7) 35 (67.3)
PTB (per punch) Low 36 (65.5) 13 (25.0) <0.0001 33 (60.0) 16 (30.8) 0.0035
High 19 (34.6) 39 (75.0) 22 (40.0) 36 (69.2)
OS Median (95%CI) 13 (9–15) 10.5 (9–12) 0.0027 12 (10–14) 10 (9–12) 0.0507
DFI Median (95%CI) 5.5 (4–7) 5 (4–6) 0.2522 6 (5–6) 5 (4–6) 0.675
L: lymphatic invasion; V: venous invasion; R: resection margin; ITB: intratumoral budding; PTB: peritumoral budding; OS: 
overall survival; DFI: Disease Free Interval
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semiautomated tissue arrayer. To exclude bias because of 
possible tumor heterogeneity, each patient had 4 tumor 
punches obtained from the tumor center and the invasive 
tumor front (2 tumor center + 2 tumor front) included 
on this array (total of 480 punches). Two additional 
one-punch TMAs were constructed including normal 
pancreatic tissue (147 punches) and precursor lesions 
(PanINs; 123 punches).
Table 3: Association of CD163 positive cells, peritumoral (p) and intratumoral (i) and 
clinicopathological features in PDAC
Feature CD163p CD163i
Freq N (%) P-value Freq N (%) P-value
Low High Low High
Gender Female 28 (47.5) 23 (46.0) 1.0 24 (44.4) 25 (48.1) 0.7121
Male 31 (52.5) 27 (54.0) 30 (55.6) 27 (51.9)
Grade G1-2 6 (10.0) 6 (12.2) 0.7179 4 (7.3) 8 (15.1) 0.4874
G3 54 (90.0) 33 (87.8) 51 (92.7) 45 (84.9)
pT pT1-2 8 (13.3) 7 (14.0) 1.0 1 (1.8) 12 (23.1) 0.0069
pT3 52 (86.7) 43 (86.0) 54 (98.2) 40 (76.9)
pN pN0 13 (21.7) 5 (10.0) 0.2041 10 (18.2) 9 (17.0) 0.8366
pN1 47 (78.3) 25 (90.0) 45 (81.8) 44 (83.3)
pM pM0 36 (61.1) 29 (58.0) 1.0 30 (54.5) 29 (54.7) 0.7179
pM1 23 (38.9) 21 (42.0) 25 (45.5) 24 (45.3)
L L0 12 (19.7) 3 (6.1) 0.1942 7 (12.7) 9 (16.9) 0.6607
L1 49 (80.3) 46 (93.9) 48 (87.3) 44 (83.1)
V V0 47 (78.3) 48 (96.0) 0.0291 49 (89.1) 43 (81.1) 0.3567
V1 13 (21.7) 2 (4.0) 6 (10.9) 10 (19.9)
R R0 43 (71.6) 37 (75.5) 0.7955 39 (70.9) 41 (77.3) 0.5523
R1 17 (28.4) 12 (24.5) 16 (29.1) 12 (22.7)
Chemotherapy None 1 (1.7) 0 (0.0) 1.0 0 (0.0) 1 (1.9) 1.0
Yes 59 (98.3) 50 (100.0) 55 (100.0) 52 (98.1)
Radiotherapy None 32 (86.5) 15 (83.3) 1.0 23 (92.0) 24 (80.0) 0.2689
Yes 5 (13.5) 3 (16.7) 2 (8.0) 6 (20.0)
Budding 10-in-10 Low 13 (21.6) 24 (48.0) 0.0155 17 (30.9) 17 (32.1) 1.0
High 47 (78.4) 26 (52.0) 38 (69.1) 36 (67.9)
ITB (per punch) Low 19 (31.6) 27 (57.1) 0.0253 19 (34.5) 25 (47.1) 0.365
High 41 (68.4) 22 (42.9) 36 (65.5) 28 (52.9)
PTB (per punch) Low 24 (40.0) 27 (56.0) 0.0200 32 (58.1) 18 (33.9) 0.0349
High 36 (60.0) 23 (44.0) 23 (41.9) 35 (66.1)
OS Median 
(95%CI)
10 (9–12) 13 (10–15) 0.0823 12 (9–15) 11 (9–13) 0.562
DFI Median 
(95%CI)
5 (4–6) 6 (4–8) 0.3054 5 (4–6) 6 (4–6) 0.7789
L: lymphatic invasion; V: venous invasion; R: resection margin; ITB: intratumoral budding; PTB: peritumoral budding; OS: 
overall survival; DFI: Disease Free Interval
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Immunohistochemistry
TMA blocks were cut at 4 μm and immunostained 
for CD4 (CD4/4B12, 1:100, pre-treatment with Tris buffer 
at 95° for 20 minutes; AEC chromogen), and FOXP3 
(Abcam, clone 236A/E7, 1:100, pre-treatment in citrate 
buffer, 30’, 100°C) as well as iNOS (iNOS, 1:100, pre-
treatment in Tris buffer, 20’, 95°C) and CD163 (CD163+; 
Novocastra, NCL-CD163CD163+;1:100, pre-treatment in 
Tris buffer, 20’, 95°C). Staining was performed using a 
Bond Max Autostainer (LEICA Bond III platform) from 
Leica Microsystem (Wetzlar, Germany). Haematoxylin 
counterstaining was performed. A double immunostaining 
procedure using anti-CD8 (Dako CD8/144B, 1:100, 
pre-treatment with Tris buffer at 95° for 20 minutes; AEC 
chromogen) and pan-cytokeratin (AE1/AE3, Dako, 1:400, 
pre-treatment with Tris buffer at 100° for 20 minutes) to 
facilitate visualization of tumor buds at the invasive front 
was carried out on one representative TMA slide according 
to a previously described protocol [22].
Negative controls were obtained by staining the 
slides with an isotype IgG for the same species (ms IgG1 
for FOXP3 and CD163, ms IgG1 kappa for CD4 and CD8 
and rb IgG for iNOS). No false-positive staining was noted.
Assessment of tumor budding
Tumor budding was defined as detached single 
cells or clusters of < 5 cells. Cases have already been 
evaluated for tumor budding using a 10-in-10 approach 
Table 4: Multivariate analysis of FOXP3p in PDAC patients
HR (95%CI) P-value
FOXP3p Low 1.0 0.0028
High 2.03 (1.3–3.2)
pT pT1-2 1.0 0.9557
pT3 1.02 (0.47–2.24)
pN pN0 1.0 0.9418
pN1 1.02 (0.57–1.82)
pM pM0 1.0 0.0001
pM1 8.54 (2.9–5.6)
Budding Low 1.0 0.0002
High 3.34 (1.78–6.3)
Chemotherapy No 1.0
Yes 0.05 (0.01–0.3) 0.0013
Figure 4: Kaplan-Meier curve indicating the prognostic effect of peritumoral FOXP3+T-cell infiltrates on outcome of 
PDAC patients. Patients with low FOXP3+T-cell counts exhibit significantly longer survival (p = 0.027).
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by using whole tissue sections immunostained for 
AE1/AE3 (pan-cytokeratin). Briefly, the 10 densest 
hot-spots of tumor budding were evaluated at high-
magnification (40x, 0.55mm2) and counted. The average 
number of buds per case was obtained. Using a receiver 
operating characteristic (ROC) curve approach, a cut-
off score of 10 buds on average was identified as most 
discriminatory for survival. Cases with an average of 
>10 buds were classified as “high-grade” budders; those 
with ≤ 10 buds were assigned as “low-grade” budders 
[20]. Additionally, tumor budding was re-evaluated 
in the TMAs by counting the number of tumor buds 
in the punches obtained from the main tumor body 
(intratumoral budding or ITB) and from the tumor front 
(peritumoral budding or PTB). The average number of 
tumor buds was calculated across all punches from the 
same localization.
Assessment of immunostaining
The immune cell infiltrates were evaluated by 
counting the number of positive cells per tissue microarray 
punch. In the case of multiple tumor punches per 
localization, the average number was calculated across 
all punches from the same localization. The end result 
was that each patient had a final score for the main tumor 
body, the tumor buds, the precursor lesions (PanINs) 
and the non-neoplastic pancreatic tissue. Evaluation 
was performed blinded to clinical endpoints. Counts 
were normalized for the percentage of tumor/spot and 
associated with the clinico-pathological features, including 
peritumoral (PTB) and intratumoral (ITB) (EMT)-Type 
tumor-budding, outcome and therapy.
Statistical analysis
In order to determine a valid cut-off score for 
immune cell counts (low/high), the median normalized 
values were used (Suppl. Table 5). Association of immune 
cell counts with categorical clinicopathological features was 
performed using the Chi-Square test and the Fisher’s Exact 
tests; for continuous variables such as age and tumor size, 
the non-parametric Wilcoxon’s Rank Sum test was used. 
For matched analyses, the Wilcoxon’s Signed Rank test for 
pairs and the Friedman test for three of more groups were 
used. Logistic regression analysis was used to determine 
the odds ratio (OR) and 95%CI with clinicopathological 
features. Missing data were few and were assumed to be 
missing at random. No imputation for missing values was 
performed. Univariate survival time analysis was performed 
using the log-rank test and differences plotted using Kaplan-
Meier curves. P-values < 0.05 were considered statistically 
significant. Correction for multiple hypothesis testing was 
not carried out [41]. Analyses were carried out using SAS 
(V9.2; The SAS Institute, Cary, NC).
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